The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
Regeneron is facing two FDA decisions for its T-cell engagers.
The Avanzar study could read out shortly.
Satri-cel is filed for gastric cancer approval in China.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.